Summary:
A randomized, double-blind, 5-arm, parallel-group, 26-week, multicenter study to evaluate the efficacy, safety, and tolerability of Canagliflozin in combination with Metformin as initial combination therapy in the treatment of subjects with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise.
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Have type 2 diabetes mellitus with inadequate glycemic control on diet and exercise
•
NOT be on AHA therapy(off for at least 12 weeks before screening), AHA therapy are Antihyperglycemic Agents such as Metformin or Sitagliptin
Qualified Participants May Receive:
$41 per completed visit for a total of 9 visits.